Why the study?
Haemorrhagic protein-losing enteropathy with transfusion dependence is a debilitating complication of complex congenital heart disease caused by elevated central venous pressure, prompting evaluation of SGLT2 inhibitors for refractory disease.
Population
2 women (ages 22 and 35 years) with CHD and transfusion-dependent refractory hPLE
Design
Case series
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors merit consideration in refractory cases; hypothesis-generating for congenital heart disease and requires prospective validation.
Background Haemorrhagic protein-losing enteropathy (hPLE) with transfusion dependence is an extreme phenotype of PLE, which is caused by elevated central venous pressure (CVP) and is a debilitating, complex congenital heart disease (CHD) complication. We report cases in which sodium–glucose cotransporter 2 inhibitor (SGLT2i) use induced hPLE remission. Case Summary Patient 1: The patient, a 22-year-old woman, had restrictive physiology after surgery for Shone’s complex with hPLE. Despite intensive diuretic treatment, she had massive ascites with a high CVP (16 mmHg) and required transfusions almost daily for 2 years. Patient 2: The patient, a 35-year-old woman, presented with hPLE after conversion of an atriopulmonary connection Fontan surgery to a total cavopulmonary connection. She also had a high CVP (25 mmHg), developed hPLE with transfusion dependence and had been receiving transfusions for 2 years. SGLT2i treatment was initiated for both patients, and they showed a marked diuretic response, leading to significant decongestion and weight loss. Gastrointestinal bleeding subsequently subsided. The patients’ haemoglobin levels stabilised without further transfusions, and serum albumin levels significantly improved, indicating hPLE reversal. Discussion SGLT2is are highly effective in treating hPLE due to various congestive CHDs. The findings suggest that the SGLT2i therapeutic effects in hPLE may be mediated by potent reduction of CVP and interstitial congestion. Thus, SGLT2is may be an innovative treatment for refractory hPLE in patients with congestive CHD, regardless of whether they have undergone the Fontan procedure.
No takes yet. Share an insight, caveat, or question.
Morimoto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: